- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Kardigan, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.09. | Kardigan auf Cantor-Konferenz: Plattformansatz für Herzmedikamente | 1 | Investing.com Deutsch | ||
| 17.08. | Citi agrees to acquire Kard Financial for commerce rewards | 3 | The Paypers | ||
| 14.08. | Citi to acquire US rewards tech company Kard Financial | 4 | FinTech Futures | ||
| KARDIGAN Aktie jetzt für 0€ handeln | |||||
| 14.08. | Citi To Acquire Kard To Supercharge Personalized Rewards And Commerce Media | 3 | pulse2.com | ||
| 14.08. | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | 906 | AFX News | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| 13.08. | Citi to acquire commerce rewards platform Kard Financial | 4 | Investing.com | ||
| 13.08. | Citigroup übernimmt Commerce-Prämienplattform Kard Financial | 3 | Investing.com Deutsch | ||
| 11.08. | Kardigan, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 11.08. | Kardigan, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.07. | TD Cowen initiates Kardigan stock with buy rating on cardiology pipeline | 2 | Investing.com | ||
| 13.07. | Kardigan: TD Cowen startet Coverage mit Kaufempfehlung - Kardiologie-Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 13.07. | Jefferies initiates Kardigan stock with buy rating on cardiology pipeline | 1 | Investing.com | ||
| 13.07. | JPMorgan initiates Kardigan stock with overweight on pipeline | 2 | Investing.com | ||
| 13.07. | Jefferies startet Kardigan mit Kaufempfehlung - Kardiologie-Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 13.07. | JPMorgan startet Kardigan-Aktie mit "Overweight" - Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 23.06. | How Kardigan spun deal leftovers into a $400M IPO | 1 | BioPharma Dive | ||
| 23.06. | Kardigan, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.06. | Kardigan erzielt 460 Millionen US-Dollar bei Börsengang an der NASDAQ | 2 | Investing.com Deutsch | ||
| 22.06. | Kardigan closes $460 million IPO on Nasdaq | 1 | Investing.com |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EYEPOINT | 2,780 | -0,71 % | XFRA PV3B: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 36,910 | -1,86 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen | |
| FILANA THERAPEUTICS | 0,789 | +1,81 % | XFRA PX91: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,300 | +1,23 % | Ironwood Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript | ||
| GALECTIN THERAPEUTICS | 3,300 | 0,00 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update | NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... ► Artikel lesen | |
| NRX PHARMACEUTICALS | 2,540 | -0,59 % | NRX Pharmaceuticals, Inc. - 8-K, Current Report | ||
| GRACE THERAPEUTICS | 2,050 | -0,49 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 9,360 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders | Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia
SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics... ► Artikel lesen | |
| INMED PHARMACEUTICALS | 1,230 | 0,00 % | InMed Pharmaceuticals Inc. - S-4/A, Registration of securities, business combinations | ||
| ELEDON PHARMACEUTICALS | 2,200 | 0,00 % | Eledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting | ||
| HERON THERAPEUTICS | 0,325 | -0,37 % | HERON THERAPEUTICS, INC. /DE/ - 8-K, Current Report | ||
| INVENTIVA | 3,065 | +1,66 % | Inventiva (IVA): How Much Is One Make-or-Break Readout Really Worth? | ||
| MEDICINOVA | 1,740 | -0,85 % | H.C. Wainwright reiterates Buy on MediciNova stock, $10 target | ||
| MILESTONE PHARMACEUTICALS | 0,780 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR | MONTREAL and CHARLOTTE, N.C., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 2,010 | 0,00 % | Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen KARDIGAN INC kann der Branche Pharma zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,020 (+0,13 %) liegt der Kurs bei 15,260 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KARDIGAN INC finden Sie auf Wallstreet Online.